Molecular Pharmacology (USA), Ltd.
Molecular Pharmacology (USA), Ltd. (MLPH) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
mlph · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Molecular Pharmacology (USA), Ltd. (MLPH) measures how much investors pay for each dollar of the company's trailing earnings. MLPH's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of -$0.00.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2002 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Molecular Pharmacology (USA), Ltd.You MLPH | $0M | N/A | — | -$0.00 |
 Acro Biomedical Co., Ltd. ACBM | $2M | N/A | — | -$0.00 |
 Affymax, Inc. AFFY | $0M | N/A | — | -$0.39 |
 Amarantus BioScience Holdings, Inc. AMBS | $0M | N/A | — | -$0.01 |
 Baseline Productions, Inc. BSSP | $0M | N/A | — | -$0.01 |
 Itoco Inc. ITMC | $0M | N/A | — | -$0.01 |
 LadRx Corporation LADX | $0M | N/A | — | -$3210.89 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $-0.00 | — | |
2023-12-31 FY2023 | — | $-0.00 | — | |
2022-12-31 FY2022 | — | $-0.00 | — | |
2014-06-30 FY2014 | — | $-0.00 | — | |
2013-06-30 FY2013 | — | $-0.00 | — | |
2012-06-30 FY2012 | — | $-0.00 | — | |
2011-06-30 FY2011 | — | $-0.00 | — | |
2010-06-30 FY2010 | — | $-0.00 | — | |
2009-06-30 FY2009 | — | $-0.00 | — | |
2008-06-30 FY2008 | 44.77x | $0.00 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Molecular Pharmacology (USA), Ltd. (MLPH) measures how much investors pay for each dollar of the company's trailing earnings. MLPH's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of -$0.00.
Frequently asked questions
MLPH pe ratio · 6 questionsMLPH's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.00 and TTM EPS of -$0.00. Data sourced from Financial Modeling Prep via MLPH's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Molecular Pharmacology (USA), Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08